Answers are grounded in this paper and cite their sources.
The rate of MPR in ESCC patients reached 42.11%. The use of the NACI regimen did not increase the occurrence of complications in neoadjuvant treatment and operation, and the SLD regression rate has a certain guiding significance for the effect of immunotherapy.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: